MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
*Driving Forces: Market Research, Intelligence, Analysis, Datapoints, Databases & Trends
2023: Top 20 Genomics Companies in the World
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)*
Organization & Developments: Ginkgo Bioworks
Parents
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)*
Children
*AI and synthetic biology platform for mRNA vaccine development.
*Ginkgo Bioworks is a biotech company founded by scientists from MIT and headed by Tom Knight.
*Ginkgo Bioworks is scaling up using significant automation for handling samples and high-throughput, next-generation sequencing technologies to process tens of thousands of individual tests at once.
*Ginkgo increasingly sees itself as a "platform," charging customers for the use of its biological foundry "like AWS does for data center cycles."
*It takes advantage of the growing ability of scientists to design and print DNA on demand — the field now known as synthetic biology.
*Project Goal: To develop genetically engineered measurement technologies for real-time monitoring of cellular health and production capacity during the manufacturing of therapeutic proteins.
*The company is expected scale up to 50,000 tests per day in September 2020 and 100,000 per day by the end of the year.
*The company specializes in using genetic engineering to produce bacteria with industrial applications.
*Volatile Reporters for Monitoring Biomanufacturing of Therapeutic Proteins Ginkgo BioWorks (Boston, Mass.) * Project length: 2 years * Requested TIP funding = $1 M * Project total (est.): $2.3 M
*Working with universities, schools, public or private companies and local communities, Ginkgo Bioworks will provide end-to-end sample collection and report results within 24-48 hours from sample receipt.
2019: That makes Ginkgo the second-most valuable VC-backed biotech startup in the U.S., behind Samumed in San Diego, which PitchBook says is worth $12.4 billion.
2020: After Kodak debacle, US lends $1.1B to a synthetic biology company and their big Covid-19, mRNA plans
2020: Ginkgo Bioworks Awarded $40MM NIH RADx-ATP Contract to Expand High Throughput SARS-CoV-2 Testing
2021: Ginkgo — the first synbio unicorn — was most recently valued privately at $4.86 billion.
2021: The company received a $1.1 billion loan in November 2020 from the U.S. International Development Finance Corporation to optimize COVID-19 vaccine manufacture and expand testing efforts.
2022: Ginkgo Bioworks Acquires Altar and Circularis
2022: Ginkgo Bioworks Holdings, Inc. 2022 Q3 - Results - Earnings Call Presentation_ seekingalpha.com
2022: Ginkgo Bioworks: Business Model Uncertainty_seekingalpha.com
2022: Ginkgo Bioworks: May The Ginkgo King Grow_ seekingalpha.com
2022: Ginkgo Bioworks: Time To Buy_seekingalpha.com
2022: Ginkgo inks $144M deal with Merck to engineer enzymes to improve ingredient manufacturing
2022: Synlogic Announces Synthetic Biotic for Gout Developed in Partnership with Ginkgo Bioworks
2022: Synlogic, Ginkgo Bioworks develop SYNB2081 to treat gout
2023: Ginkgo Bioworks inks AI partnership with Google Cloud_seekingalpha
2023: Ginkgo Bioworks Provides Preliminary Unaudited 2022 Revenue Highlights and Business Review
2023: Ginkgo Bioworks Receives Grant to Develop Innovative Live Cell Delivery Platform of Antibody Therapeutics for Treating HIV and Malaria
2023: Ginkgo Bioworks: A Long Way To Go_ seekingalpha.com
2023: Ginkgo Bioworks: Products Progressing Towards Market (NYSE:DNA)
2023: Ginkgo Bioworks: Strategic Shifts Amidst Financial Uncertainty_ seekingalpha.com
2023: IARPA Awards B24IC Research Contract to Ginkgo Bioworks to Develop Breakthrough Biointelligence and Biosecurity Innovations
2023: Merck, Ginkgo Bioworks strike deal worth up to $490M to 'optimize' biologics manufacturing
2024: Collaboration between Merck and Ginkgo Bioworks for Improving Biologics Manufacturing Achieves First Milestone
2024: Ginkgo Bioworks Acquires Modulus Therapeutics' Cell Therapy Assets to Strengthen Next-Gen CAR Designs
2024: Ginkgo Bioworks At The Intersection Of Cutting-Edge Technology And Financial Disappointment_
2024: Ginkgo Bioworks Holdings, Inc. 2023 Q4 - Results - Earnings Call Presentation
2024: Ginkgo Bioworks rolls out a new API for synthetic biology AI models
2024: Ginkgo Bioworks Secures $9M Milestone Payment from Merck Partnership Breakthrough
2024: Ginkgo Bioworks: From Growth To Value
2024: Ginkgo Bioworks: Multiple Red Flags
2024: Ginkgo Bioworks: Unproven Transition But 2025 Is Looking Better_ seekingalpha.com
2024: Ginkgo job cuts to hit at least 35% of workforce
2024: Ginkgo wins DARPA contract to develop de-icing products
2025: 2025 Is Make Or Break For Ginkgo Bioworks
2025: Ginkgo Bioworks: Cost-Cutting Efforts Aren't Enough
2025: Ginkgo Bioworks: Declining Core Revenue And High Cash Burn Echo Amyris' Path
Ginkgo Datapoints
Jumps
*Key People: Ginkgo Bioworks
Finance & Acquisitions: Ginkgo Bioworks